The performance of pre-delivery serum concentrations of angiogenic factors in predicting postpartum antihypertensive drug therapy following abdominal delivery in severe preeclampsia and normotensive pregnancy

Nnabuike Chibuoke Ngene1,*, Jagidesa Moodley2, Thajasvarie Naicker3

1 Department of Obstetrics and Gynaecology, University of KwaZulu-Natal, South Africa, 2 Women’s Health and HIV Research Group, Department of Obstetrics and Gynaecology, University of KwaZulu-Natal, South Africa, 3 Department of Optics and Imaging, University of KwaZulu-Natal, South Africa

* ngenenc@gmail.com

Abstract

Background
The imbalance between circulating concentrations of anti- and pro-angiogenic factors is usually intense in preeclampsia with severe features (sPE). It is possible that pre-delivery circulating levels of angiogenic factors in sPE may be associated with postpartum antihypertensive drug requirements.

Objective
To determine the predictive association between maternal pre-delivery serum concentrations of angiogenic factors and the use of \( \geq 3 \) slow- and/or a rapid-acting antihypertensive drug therapy in sPE on postpartum days zero to three following caesarean delivery.

Study design
Women with sPE (n = 50) and normotensive pregnancies (n = 90) were recruited prior to childbirth. Serum samples were obtained from each participant < 48 hours before delivery to assess the concentrations of placental growth factor (PIGF) and soluble fms-like tyrosine kinase-1 (sFlt-1) using the Roche Elecsys platform. Each participant was followed up on postpartum days zero, one, two and three to monitor BP and confirm antihypertensive treatment. The optimal cut-off thresholds of sFlt-1/PIGF ratio from receiver operating characteristic curve predictive of the antihypertensive therapy were subjected to diagnostic accuracy assessment.
**Results**

The majority 58% (29/50) of sPE had multiple severe features of preeclampsia in the antenatal period with the commonest presentation being severe hypertension in 88% (44/50) of this group, followed by features of impending eclampsia which occurred in 42% (21/50). The median gestational age at delivery was 38 (Interquartile range, IQR 1) vs 36 (IQR 6) weeks, \( p < 0.001 \) in normotensive and sPE groups respectively. Notably, the median sFlt-1/PIGF ratio in normotensive and sPE groups were 7.3 (IQR 17.9) and 179.1 (IQR 271.2) respectively, \( p < 0.001 \). Of the 50 sPE participants, 34% (17/50) had early-onset preeclampsia. The median (IQR) of sFlt-1/PIGF in the early- and late-onset preeclampsia groups were 313.52 (502.25), and 166.59(195.37) respectively, \( p = 0.006 \). From postpartum days zero to three, 48% (24/50) of sPE received \( \geq 3 \) slow- and/or a rapid-acting antihypertensive drug. However, the daily administration of \( \geq 3 \) slow and/or a rapid-acting antihypertensive drug in sPE were pre-delivery 26% (13/50), postpartum day zero 18% (9/50), postpartum day one 34% (17/50), postpartum day two 24% (12/50) and postpartum day three 20% (10/50). In sPE, the pre-delivery sFlt-1/PIGF ratio was predictive of administration of \( \geq 3 \) slow- and/or a rapid-acting antihypertensive drug on postpartum days zero, one and two with the optimal cut-off ratio being \( \geq 315.0, \geq 181.5 \) and \( \geq 267.8 \) respectively (sensitivity 72.7–75.0%, specificity 64.7–78.6%, positive predictive value 40.0–50.0% and negative predictive value 84.6% - 94.3%). The predictive performance of sFlt-1/PIGF ratio on postpartum day 3 among the sPE was not statistically significant (area under receiver operating characteristic curve, 0.6; 95% CI, 0.3–0.8).

**Conclusion**

A pre-delivery sFlt-1/PIGF ratio (\( < 181.5 \)) is a promising predictor for excluding the need for \( \geq 3 \) slow- and/or a rapid-acting antihypertensive drug therapy in the immediate postpartum period in sPE.

**Introduction**

The pathogenesis of preeclampsia (PE) is not yet completely understood; however, recent evidence suggests that the disease manifests in a susceptible mother following inadequate placentation that results in abnormal placental blood flow [1, 2]. Consequently, syncytiotrophoblast damage occurs leading to an elevation in the secretion of anti-angiogenic factors such as soluble fms-like tyrosine kinase-1 (sFlt-1) and a concurrent reduction in the levels of pro-angiogenic factors such as vascular endothelial growth (VEGF) and placental growth factors (PIGF) [3–5]. The findings of earlier studies were contributory to the current knowledge [6, 7].

The imbalance between pro- and anti-angiogenic factors in PE is known to develop long before the manifestation of the symptomatology [8] and correlates with the severity of the disease [9]. As a result, the imbalance in the circulating concentrations of angiogenic factors (sFlt-1/PIGF ratio) is usually intense in PE with severe features (i.e. severe preeclampsia, sPE) compared to those without these features [10–12]. It is established that most cases of postpartum eclampsia occur within the first 48 to 72 hours of childbirth [13, 14] and that the systemic concentration of sFlt-1 reverts to baseline within 48 to 72 hours post-delivery [3, 15]. Evidence
also suggests that blood pressure (BP) is influenced by the circulating concentration of pro- and anti-angiogenic factors; PIGF reduces while sFlt-1 increases BP [16, 17]. This association between BP and angiogenic factors has been reported in women who underwent caesarean deliveries (CD) [18]. For instance, a report on singleton pregnancies delivered by CD found that antenatal circulating angiogenic factors correlate with the highest postpartum systolic and diastolic BPs [19]. Despite these findings, there are variations in the circulating concentrations of angiogenic factors amongst racial groups [20]. As a result, a clarion call to determine the circulating concentrations of angiogenic factors in different racial groups has been advocated [21] and this is of particular importance in settings with high burden of PE and diverse populations such as South Africa [22–25].

Given that the more intense the imbalance in angiogenic factors the greater the severity of the PE [11], and that antenatal circulating concentrations of these biomarkers correlate with postpartum BP, it is possible that a clinically useful predictive association exists between pre-delivery levels of angiogenic factors and postpartum BP in sPE. Undoubtedly, the administration of antihypertensive drug therapy reduces high BP. An already reduced postpartum BP may therefore not show a clinically useful predictive association with the degree of pre-delivery imbalance in angiogenic factors. Furthermore, patients with difficult-to-control hypertension usually require combined antihypertensive medications [26]. Also, the number of antihypertensive medications and their type of action (slow- or rapid-acting) depicts the severity of the hypertension and possibly the extent of imbalance in angiogenic factors. Therefore, an appropriate surrogate marker of the association between pre-delivery angiogenic imbalance and postpartum BP may be the number and type of antihypertensive medication. A finding of a predictive association between the pre-delivery angiogenic factors and postpartum antihypertensive drug requirements will assist in patient counselling and serve as a triage to ensure advance management plans (such as obstetric high care admission) for those who require ≥ 3 slow-acting and/or any rapid-acting antihypertensive medication. In South Africa, obstetric high care units are scarce resources with the number of patients that require admission therein frequently exceeding the number of available beds [27]. The majority of the patients in many of these high care units are usually those with sPE who may require ≥ 3 slow-acting and/or any rapid-acting antihypertensive medication for severe hypertension. It is possible that the pre-delivery imbalance in angiogenic factors may be valuable as a triage test to predict patients with sPE that may be managed in an ordinary hospital ward whenever the number of beds in the obstetric high care unit is insufficient.

Of note, the sFlt-1/PIGF ratio has been reported to be a better predictor of pregnancy complications than sFlt-1 or PIGF alone [28, 29], and different sFlt-1/PIGF ratios varying from $\geq 85 - \geq 871$ pg/ml have been used to predict adverse maternal outcomes in PE [30]. Unfortunately, there is no approved reference standard for the prediction of postpartum antihypertensive drug requirement. With this in mind, the aim of this study was to determine the relationship between maternal pre-delivery serum levels of angiogenic factors (sFlt/PIGF ratio) and BP on postpartum days 0–3 amongst severe preeclamptic and healthy normotensive pregnant women who had CD, using the number and type of antihypertensive medication as an outcome measure of the BP. The predelivery serum concentration of PIGF, sFlt-1 and sFlt-1/PIGF ratio in the normotensive and sPE groups were also compared.

**Materials and methods**

**Study design, duration and setting**

This was a prospective cohort study conducted between August—December 2015 in a regional hospital in South Africa.
Regulatory permission

Ethical approval (reference BE236/14) to conduct the study was obtained from the Biomedical Research Ethics Committee of the University of KwaZulu-Natal, South Africa. All participants gave written informed consent prior to the study.

Study participants

The study participants were a homogenous group of Black South Africans and included consecutive women with sPE and normotensive pregnancies who were scheduled for CD. Exclusion criteria included active phase of labour, other types of hypertensive disorders of pregnancy (such as eclampsia, PE without severe features, gestational hypertension, and chronic hypertension), diabetes, multiple pregnancy, and illness from other medical conditions. Angiogenic imbalance is usually less intense in PE without severe features [12], therefore, we excluded this group of patients.

Pre-eclampsia was defined as the development of new-onset hypertension (BP $\geq$140/90 mmHg) after 20 weeks of gestation with any of the following: proteinuria ($\geq$ 300 mg in a 24 hours urine sample), fetal growth restriction and maternal organ dysfunction (renal impairment, elevated liver transaminases, haematological disorder such as thrombocytopenia, and cerebral symptoms suggestive of impending eclampsia) [31]. sPE was defined based on the presence of the following features: systolic BP $\geq$ 160 mmHg and or diastolic BP $\geq$ 110 mmHg, serum creatinine $\geq$ 90–110 mmol/L [31–33], elevated liver transaminases $\geq$ 70 IU/L [32, 34], platelet count $< 100 \times 10^9$ /L [35], HELLP syndrome, pulmonary oedema, impending eclampsia, fetal growth restriction [36], and proteinuria $\geq$ 3 g/24 hours. The differences in the diagnostic criteria for sPE [31, 35–37] are known including the recent European guideline that recommends increased surveillance if 24 hours urine protein exceed 2g [38]. Our diagnostic criteria were supported by the high incidence [24, 25] and burden [22] of PE in our setting and its tendency to deteriorate rapidly [23]. Early onset PE (EOPE) was defined as the development of PE at $< 34$ weeks of gestation. Late onset PE (LOPE) was defined as the development of PE at $\geq 34$ gestational weeks. The severe complications of PE as recommended by the International Society for the Study of Hypertension in Pregnancy (ISSHP) that were used to determine timing of delivery included: gestational age $< 24$ weeks and/or $\geq 34$ weeks, inability to control the BP with maximum dose of three antihypertensive drugs from different classes, pulmonary oedema, HELLP syndrome, progressive deterioration in maternal condition (liver, renal, imminent eclampsia, and/or platelet count), placental abruption, and fetal compromise/demise [31].

Data collection

Prior to delivery ($< 48$ hours), serum sample was collected from each participant for measurement of sFlt-1 and PIGF concentrations. The details of this process are explained in the next subheading (measurement of sFlt-1/PIGF ratio). Additionally, the BP of participants were measured during the pre-delivery period and on days 0, 1, 2 and 3 post-delivery. Day 0 refers to the day of delivery while the next consecutive three days were day 1, day 2 and day 3 post-delivery. The BP was measured using iMEC12 patient monitor (Shenzhen Mindray Bio-Medical Electronics Co., Ltd), an automated device which has passed a baseline check [39]. Each day, the BP was measured at 05:00, 08:00, 14:00 and 22:00 hours. Two measurements were taken at rest from the arm of each participant using an appropriate cuff and the BP at each point time was the average readings [40]. The antihypertensive drug therapy administered to the participants prior to delivery and on postpartum days 0–3 were also monitored and the
information retrieved from the patients' hospital charts. A dedicated and trained research midwife assisted with data collection and recording of the information in a data extraction form.

**Measurement of sFlt-1/PIGF ratio**

Each participant had a peripheral venous blood sample collected using SST II advance yellow with gel tubes. The blood sample was centrifuged at 3000 rpm at room temperature for 10 minutes in a Rotina 380 R benchtop centrifuge (Andreas Hettich GmbH & Co. KG, Germany). The serum was collected and stored at -20˚C. Measurement of the angiogenic factors were performed in batches within one month of specimen collection. An independent laboratory, Ampath laboratory (Durban, South Africa), determined the concentration of sFlt-1 and PIGF using the Roche Elecsys platform (Roche Diagnostics, Germany) according to the instructions of the manufacturer which were based on sandwich principle [41, 42]. The ability of sFlt-1/PIGF ratio as a predictor of the target condition (use of ≥3 slow- and/or any rapid-acting antihypertensive drug in the postpartum period) was statistically evaluated.

**Postpartum antihypertensive therapy**

The treatment of the hypertension was guided by national guidelines published/endorsed by the South African department of health [40, 43]. Gradual dose reduction and final withdrawal of antihypertensive drugs were commenced in the postpartum period following normalization of the BP. The clinicians were responsible for the prescription (including the gradual withdrawal) of antihypertensives medications for the patients. Antihypertensive medication was indicated to treat postpartum BP ≥ 150/100 mmHg [32, 44]. However, BP 140-150/90-100 mmHg was treated amidst complications such as severe thrombocytopaenia (to prevent cerebrovascular accident) and renal impairment. Severe hypertension in pregnancy (BP ≥ 160/110 mmHg) is an emergency that requires rapid but controlled reduction of the high BP to achieve a target BP of 140-150/90-100 mmHg [43, 45, 46]. Therefore, the criteria that had been used to determine the use of ≥3 slow- and/or a rapid-acting antihypertensive drug therapy were the severity of the hypertension and the presence of other target organ complications. The antihypertensive drugs of choice for severe hypertension were intravenous labetalol or rapid-acting nifedipine. Other slow-acting antihypertensives agents were introduced sequentially to improve drug efficacy and maintain the BP control. For non-severe hypertension in the postpartum period, the commonly prescribed slow-acting antihypertensive drug was a calcium channel blocker (amlodipine or extended release nifedipine). Other slow-acting antihypertensive agents used were monohydralazine, prazosin, enalapril, alpha methyl dopa, and diuretics such as hydrochlorothiazide.

**Statistical analysis**

The analysis of data was performed using SPSS version 24.0 (IBM, Armonk, NY, USA) except for utilizing proc glimmix [47] in SAS 9.4 (SAS Institute Inc. Cary, NC, USA) to fit the logistic model for time-dependent receiver operating characteristic (ROC) curve. Normality in the distribution of data were assessed graphically and with the use of Shapiro-Wilk test [48]. Descriptive statistics were also performed. The differences between sPE and normotensive groups were assessed using student t-test if the data was continuous and normally distributed or using Mann-Whitney U test if the data was continuous and skewed. The differences in categorical variables between the two groups were assessed using the Chi-square test, or Fischer exact test when the frequency within a cell is <5. Repeated measures two-way analysis of variance (ANOVA) was conducted to compare the highest and lowest postpartum BPs of the two groups. The correlation between pre-delivery sFlt-1/PIGF ratio and highest postpartum BPs
were assessed using Spearman’s rank correlation which is appropriate for two continuous variables with either or both being non-normally distributed [49–51]. The predictive performance of the sFlt-1/PIGF ratios were assessed using AUC (area under the curve) of ROC curves [52, 53]. Data-driven optimal cut-off threshold [49, 54] of sFlt-1/PIGF ratio was obtained at maximal Youden index (Sensitivity + Specificity - 1) [55] in the daily ROC curve coordinate. The diagnostic accuracy of the cut-off threshold was assessed and reported as positive, and negative predictive values, sensitivity, and specificity [56]. The STARD (Standards for Reporting of Diagnostic Accuracy) guideline [57] was applied in this report and the requirements in its checklist [58] satisfied.

Results
The flow diagram of the study participants is shown in Fig 1.

Demographics
The median age of the participants was 28 (Interquartile range, IQR 7) and 23 (IQR 11) years for the normotensive and sPE groups respectively, \( p = 0.001 \). Primigravidae constituted 8.9\% (8/90) and 46\% (23/50) of the normotensive and sPE groups respectively, \( p < 0.001 \). The body mass index at first prenatal visit for normotensive vs sPE groups was 29.5 (IQR 8.3) vs 26.8 (IQR 6) respectively, \( p = 0.028 \). Of the 50 sPE participants, 17 had EOPE. The majority (29/50) of sPE had multiple severe features with the commonest presentation being severe hypertension (44/50), followed by neurological signs and symptoms of impending eclampsia (21/50). The median gestational age at delivery was 38 (IQR 1) vs 36 (IQR 6) weeks, \( p < 0.001 \) in normotensive and sPE groups respectively. The indications for CD (fetal, maternal, and feto-maternal) in normotensive vs sPE were 14.4\% (13/90), 78.9\% (71/90) and 6.7\% (6/90) vs 40\% (20/50), 46\% (23/50), and 14\% (7/50) respectively, \( p < 0.001 \).

Prenatal supplementation
Prenatal aspirin therapy to prevent PE was received by 2.2\% (2/90) and 4\% (2/50) of normotensive and sPE respectively, \( p = 0.67 \). Additionally, prenatal calcium supplementation for prevention of PE was administered to 94.4\% (85/90) and 84\% (42/50) of the normotensive and sPE groups respectively, \( p = 0.041 \).

sFlt-1/PIGF ratio
The population reference values of angiogenic factors at different weeks of gestation before delivery (guided by the time of peak and trough of circulating concentrations of sFlt-1 and PIGF [21], and also by the categorization of PE into early- and late-onset disease, as well as classification of pregnancies into term and post-term) is shown in Table 1. There were no missing data. The median sFlt-1/PIGF ratio in normotensive and sPE groups were 7.3 (IQR 17.9) and 179.1 (IQR 271.2) respectively, \( p < 0.001 \). Further assessment showed that the sFlt-1/PIGF ratio of the two normotensive participants on aspirin were 38.55 and 6.95. On the other hand, the sFlt-1/PIGF ratio of the two sPE participants on aspirin were 117.79 and 90.44.

Postpartum blood pressure and sFlt-1/PIGF ratio
The highest and lowest BPs on postpartum days 0–3 are illustrated in Table 2. Additionally, Table 3 shows the correlation between predelivery sFlt-1/PIGF ratio and the mean of highest and lowest blood pressures on days 0–3 postpartum. When the ability of sFlt-1/PIGF ratio to
predict severe systolic and diastolic hypertension on days 0–3 postpartum were assessed, the AUC was 0.77–0.88, \( p < 0.05 \) in both groups and 0.36–0.7, \( p > 0.05 \) in sPE.

**Postpartum antihypertensive drug therapy and sFlt-1/PIGF ratio**

Of the sPE, 48% (24/50) received \( \geq 3 \) slow- and/or rapid-acting antihypertensive drug therapy on days 0–3 postpartum. One normotensive participant in the pre-delivery period developed sustained hypertension postpartum and received \(< 3 \) slow-acting antihypertensive drugs and no rapid-acting antihypertensive agent. Further details on antihypertensive drug therapy are provided in Table 4. No normotensive participant received antihypertensive therapy in the pre-delivery period. The median (IQR) of sFlt-1/PIGF ratio in participants who received \((n = 24)\) vs those who did not receive \((n = 116)\) \( \geq 3 \) slow- and/or a rapid-acting antihypertensive drug on any of postpartum days 0–3 were 267.83 (299.96) vs 13.97 (45.31), \( p < 0.001 \)

157 pregnant participants were enrolled.

17 participants were excluded
9 met the exclusion criteria
3 Had their delivery postponed
5 Had their blood not sentf or angiogenic factors assay due to logistic constraints and given attainment of sample size.

90 healthy normotensive participants included / analyzed.

50 severe preeclamptic participants included /analyzed.

Was antihypertensive drug therapy administered?

Pre-delivery:
Yes, \( n = 0 \)
No, \( n = 90 \)

Postpartum:
Yes, \( n = 1 \)
No, \( n = 89 \)

Pre-delivery:
Yes, \( n = 49 \)
No, \( n = 1 \)

Postpartum:
Yes, \( n = 49 \)
No, \( n = 1 \)

Fig 1. Study flow chart.

https://doi.org/10.1371/journal.pone.0215807.g001
The sFlt-1/PIGF ratio of the "normotensive" patient who received <3 slow-acting antihypertensive drugs in the postpartum period was 5.61. The ROC curve in Fig 2 shows the ability of sFlt-1/PIGF ratio to predict participants who had ≥3 slow- and/or a rapid-acting antihypertensive drug on postpartum days 0, 1, 2 and 3 in both the normotensive and sPE groups combined together, n = 140. In sPE group, the performance of sFlt-1/PIGF ratio in predicting the use of ≥3 slow- and/or a rapid-acting antihypertensive agent on days 0–3 postpartum is shown in Fig 3 with the area under ROC curve on day 3 being 0.6 (95% CI, 0.3–0.8) indicating a non-statistically significant AUC because the confidence interval includes 0.5 (null hypothesis = AUC of 0.5). Again, there was no participant in the normotensive group that received ≥3 slow- and/or rapid-acting antihypertensive agents. Therefore, the predictive ability of sFlt-1/PIGF ratio in the normotensive group alone could not be assessed. The area under the time-dependent ROC curves showed: both groups 0.617, p < 0.001; sPE 0.519, p = 0.088; but the normotensive group did not fit the model. The diagnostic accuracy of the optimal cut-off values of sFlt-1/PIGF ratios are shown in Table 5. For purposes of completeness, the diagnostic accuracy of the sFlt-1/PIF ratio among sPE on day 3 was calculated despite the confidence interval of the AUC on day 3 that included 0.5 (Fig 3). Nonetheless, when the sPE group was sub-categorized, the sFlt-1/PIGF ratio did not demonstrate optimal ability to predict postpartum antihypertensive requirements in EOPE (AUC 0.50–0.61, p > 0.05) and in LOPE (AUC 0.57–0.78, p > 0.05). Importantly, the median (IQR) of sFlt-1/PIGF in the EOPE and LOPE groups were 313.52 (502.25), and 166.59 (195.37) respectively, p = 0.006.

In each gestational age category ≥34 weeks, the comparison between normotensive and sPE groups for each of sFlt-1, PIGF and sFlt-1/PIGF ratio was statistically significant with p-value <0.026. Abbreviations: NA, not applicable; NP, no participant; IQR, interquartile range; PIGF, placental growth factor; sPE, preeclampsia with severe features; sFlt-1, soluble fms-like tyrosine kinase-1.
Table 2. Highest and lowest daily postpartum blood pressures.

| Postpartum day | Mean of highest postpartum BP (mmHg) | Mean lowest postpartum BP (mmHg) |
|----------------|--------------------------------------|----------------------------------|
|                | Normotensive                          | sPE                              | Normotensive                          | sPE                              |
|                | ¹Systolic BP  | ²Diastolic BP | ³Systolic BP | ⁴Diastolic BP | ¹Systolic BP | ²Diastolic BP | ³Systolic BP | ⁴Diastolic BP |
| Day 0          | 125.62 ± 14.58 | 74.91 ± 9.64 | 149.13 ± 18.26 | 91.24 ± 12.77 | 104.28 ± 11.73 | 56.31 ± 9.34 | 119.30 ± 18.42 | 68.22 ± 13.25 |
| Day 1          | 122.53 ± 13.24 | 75.21 ± 9.20 | 148.06 ± 15.73 | 94.68 ± 10.53 | 102.93 ± 11.16 | 59.10 ± 9.62 | 114.84 ± 14.59 | 68.08 ± 11.32 |
| Day 2          | 119.32 ± 14.48 | 74.75 ± 10.70 | 151.14 ± 13.82 | 93.98 ± 19.03 | 103.80 ± 11.31 | 60.64 ± 9.39 | 126.29 ± 15.30 | 74.76 ± 12.26 |
| Day 3          | 118.71 ± 12.25 | 76.64 ± 10.70 | 157.92 ± 14.10 | 101.41 ± 12.18 | 109.45 ± 10.81 | 63.95 ± 9.08 | 128.39 ± 17.97 | 80.68 ± 13.93 |

Abbreviations: BP, Blood pressure; sPE, Preeclampsia with severe features.
¹Highest systolic BP: Time had no significant effect on highest systolic BP (F-ratio 0.73, p < 0.001, η² = 0.65).
²Highest diastolic BP: There was significant effect of time (F-ratio 6.95, p < 0.001, η² = 0.64) on highest diastolic BP. The significant difference with time was noted between postpartum days 0 and 3, days 1 and 3, and days 2 and 3.
³Lowest systolic BP: There was significant effect of time (F-ratio 11.49, p < 0.001, η² = 0.14) and participant group (F-ratio 60.05, p < 0.001, η² = 0.46) on lowest systolic BP. The significant difference with time was observed between postpartum days 0 and 3, days 1 and 2, days 1 and 3, and days 2 and 3.
⁴Lowest diastolic BP: There was significant effect of time (F-ratio 12.82, p < 0.001, η² = 0.15) and participant group (F-ratio 49.21, p < 0.001, η² = 0.41) on lowest diastolic BP. The significant difference with time was noted between postpartum days 0 and 3, days 1 and 3, and days 2 and 3.

https://doi.org/10.1371/journal.pone.0215807.t002

Discussion

Angiogenic imbalance (sFlt-1/PIGF ratio) was high in sPE compared to the normotensive group with the median of the ratios being 179.1 [68]. In susceptible women, EOPE occurs due to inadequate remodelling of spiral arteries findings of other studies: EOPE 27.6% vs LOPE 72.4% [67], and EOPE 35.5% vs LOPE 64.5% [68]. In susceptible women, EOPE occurs due to inadequate remodelling of spiral arteries while LOPE develops because the placenta overgrows its blood supply or becomes senescent.

Table 3. Correlation between predelivery sFlt-1/PIGF ratio and the mean of highest or lowest blood pressures on days 0–3 postpartum.

| Mean postpartum BP | Spearman’s correlation | sPE, n = 50 |
|--------------------|------------------------|------------|
|                    | Correlation coefficient | p-value    | Correlation coefficient | p-value    | Correlation coefficient | p-value |
| Highest systolic BP| + 0.658                 | <0.001*    | + 0.136                 | 0.200      | + 0.077                 | 0.596   |
| Highest diastolic BP| + 0.647                | <0.001*    | + 0.168                 | 0.114      | + 0.217                 | 0.131   |
| Lowest systolic BP | + 0.559                 | <0.001*    | + 0.276                 | 0.008*     | + 0.101                 | 0.487   |
| Lowest diastolic BP| + 0.548                 | <0.001*    | + 0.143                 | 0.179      | + 0.046                 | 0.749   |

Abbreviation: sPE, Preeclampsia with severe features.
*Significant p-value.

https://doi.org/10.1371/journal.pone.0215807.t003
In each case, syncytiotrophoblastic stress occurs and leads to increased secretion of pro-inflammatory mediators such as sFlt-1 that propagate the clinical features of the disease [69, 70].

In the present study, severe hypertension was the commonest presenting clinical feature in 88% (44/50) of sPE. In the same group (sPE), 46% (23/50) had CD due to maternal indications. In a previous study, the frequency of maternal indications for delivery, mainly severe hypertension, exceeded fetal indications [71]. The predominance of maternal indications for delivery may be a reflection of the maternal severity of the PE which has been reported to correlate with the level of sFlt-1/PIGF ratio [9].

The present study demonstrates that in sPE, pre-delivery sFlt-1/PIGF ratio of ≥315.0, ≥181.5, ≥267.8 and ≥257.6 have high negative predictive value for administration of ≥3 slow- and/or a rapid-acting antihypertensive agents on postpartum days 0–3 respectively following CD; although this was not statistically significant on postpartum day 3 (as the confidence interval of the area under the ROC curve on day 3 [Fig 3] includes the null point of 0.5) [49] possibly due to the return of sFlt-1 to pre-pregnancy levels within 48–72 hours postpartum.

Additionally, in the combined group of sPE and normotensive pregnant women who had CD, pre-delivery sFlt-1/PIGF ratio of ≥86.5, ≥86.5, ≥81.3 and ≥61.7 have high negative predictive value to predict administration of ≥3 slow- and/or a rapid-acting antihypertensive drug therapy on postpartum days 0–3 respectively. The intended use of this test is for prediction of postpartum antihypertensive requirement but our findings show that the negative predictive value is better than the positive predictive value. The clinical role of the test is to triage pregnant women and make provision for the antihypertensive needs of those at increased risk of requiring ≥3 slow- and/or rapid-acting antihypertensive drug therapy. Although there is a tendency towards normalization of BP after delivery of the baby and placenta in PE, some women

| Category of antihypertensive drug | Number (%) of preeclampsia with severe features, n = 50 |
|-----------------------------------|-----------------------------------------------------|
| **Pre-delivery**                  |                                                     |
| None                             | 1(2)                                                |
| 1–2 non-rapid acting oral agent  | 36(72)                                               |
| ≥3 oral agent or ≥1 rapid acting agent | 13(26)                                              |
| **Postpartum day 0**              |                                                     |
| None                             | 2(4)                                                 |
| 1–2 non-rapid acting oral agent  | 39(78)                                               |
| ≥3 oral agent or ≥1 rapid acting agent | 9(18)                                               |
| **Postpartum day 1**              |                                                     |
| None                             | 9(18)                                                |
| 1–2 non-rapid acting oral agent  | 24(48)                                               |
| ≥3 oral agent or ≥1 rapid acting agent | 17(34)                                               |
| **Postpartum day 2**              |                                                     |
| None                             | 11(22)                                               |
| 1–2 non-rapid acting oral agent  | 27(54)                                               |
| ≥3 oral agent or ≥1 rapid acting agent | 12(24)                                               |
| **Postpartum day 3**              |                                                     |
| None                             | 18(36)                                               |
| 1–2 non-rapid acting oral agent  | 18(36)                                               |
| ≥3 oral agent or ≥1 rapid acting agent | 10(20)                                               |
| Missing data                     | 4(8)                                                 |

https://doi.org/10.1371/journal.pone.0215807.t004
in the puerperium may develop complications of hypertension if adequate plans are not made for their postpartum antihypertensive needs. Therefore, this screening test has a great potential in clinical practice as cost savings may accrue because triage will be possible, and low-risk women (at decreased risk of requiring ≥ 3 slow- and/or a rapid-acting antihypertensive agent) will require non-intensive monitoring and incur less cost.
The sFlt-1/PIGF ratios predictive of the postpartum antihypertensive requirement in the present study are within the range previously found to be associated with adverse maternal outcomes [30]. Previously, PIGF (≤0.4 - ≤122 pg/ml) and sFlt-1/PIGF ratios (≥85 - ≥871) have been applied to predict adverse maternal outcomes in PE [30]. Nonetheless, an sFlt-1/PIGF ratio above 655 was found to be non-predictive of impaired perinatal outcome, but the authors suggest that levels above 1000 may be useful [72]. Although PIGF may not be as good as sFlt-1/PIGF ratio, a previous study has shown that with or without PE, low PIGF (below 100

Fig 3. Area under receiver operating characteristic curve (AUC) showing the performance of sFlt-1/PIGF ratio in predicting the administration of ≥ 3 slow- and/or a rapid-acting antihypertensive drug on postpartum Day 0, Day 1, Day 2 and Day 3 in women with preeclampsia with severe features.

https://doi.org/10.1371/journal.pone.0215807.g003
pg/ml) levels signal increased risk of adverse outcomes of pregnancy [73]. Unsurprisingly in the present study, there was a sub-optimal performance [53, 54] by sFlt-1/PIGF ratio in predicting severe postpartum systolic and diastolic hypertension in sPE probably because antihypertensive medications may have modified the BP levels. The complex heterogenous pathogenesis of PE [21, 74, 75] may also account for this finding. Nonetheless, to the best of our knowledge, there is no previous study on prediction of postpartum antihypertensive drug requirements. Understandably, the prediction of pregnancy events in PE using angiogenic factors is influenced by the complex pathogenesis of the disease as well as the absent or less pronounced angiogenic imbalance in some cases called “non-angiogenic” PE (which is prevalent in LOPE associated with comorbidity such as obesity) [76]. It is possible, however, that indices such as sFlt-1/PIGF ratio, serum NT-proBNP (N-Terminal Prohormone of Brain Natriuretic Peptide), and total peripheral resistance which are predictive of hypertensive disorders of pregnancy [77] may predict antihypertensive drug requirement. Possibly, a combination of multiple factors that includes the pre-delivery sFlt-1/PIGF ratio may improve the prediction of postpartum antihypertensive medications and may even act as a marker of resistant hypertension. These require further investigation.

### Strengths and limitations

The categorization of the duration of data collection into postpartum day 0, day 1, day 2 and day 3 may influence the number of BP measurements performed on postpartum day 0 and consequently affect the day 0 mean BP. This is because the CD were performed at different time points as determined by the clinical indications. It will be unethical and harmful to defer an emergency CD of a viable fetus for the purposes of this study. Therefore, our approach...
resembles the practical situation in most clinical settings where a day of hospital stay is from 00:00 to 23:59 hours. Furthermore, apart from sFlt-1 and PIGF, factors such as fluid therapy, administration of vasoactive medications and psychological stress, to mention but a few, affect postpartum BP [17, 69, 78, 79]. Although complex, it will be beneficial for future studies to investigate the contributions of these factors in determining postpartum BP levels. Such studies may also assist to determine if there is a time lag between postpartum resolution of angiogenic imbalance and the return of BP to pre-pregnancy level.

Given the lack of an inter-class dose (efficacy) equivalent table of different types of antihypertensive agents, we did not include the strength/dosage of antihypertensive agents administered to the research participants. Regardless, there is variability in BP control response to an antihypertensive agent, with extra medication from another class of antihypertensive agent added to the drug regimen of an individual with poorly controlled hypertension. In the antepartum period, however, one is apprehensive of the possible effects of combined antihypertensive medications on the foetus but it is prudent to control BP in pregnancy and postpartum period to avert adverse outcomes such as stroke. Despite the scarcity of robust data to direct the drug treatment of hypertension during pregnancy and the puerperium [80], women in the index study were only treated with the commonly recommended antihypertensive agents with long history of safety in pregnancy.

Due to lack of hospital bed-space [81], and local challenges associated with follow-up of outpatients for research purposes it was not feasible to include women who had vaginal deliveries as research participants. The challenges with follow-up of patients also affect other disciplines in South Africa. For instance, a recent study in South Africa indicates that after a surgery for ankle fracture, 6/268 (3.3%) of the patients attended all the follow-up clinic visits while 56/268 (20.9%) did not attend any [82]. We speculate that unavailability of transport to the clinic, change of personal telephone numbers, unaffordability or unsteady use of a specified family physician, and change of residential address which makes home visit challenging are additional realities in our setting. Our feasibility study prior to the study, therefore, did not support long-term patient follow-up for the purposes of this research. Importantly, a study in the United States also indicates that the postpartum follow-up rate after sPE was 52% [83]. In our opinion, the follow-up rate for HDP is challenging because hypertension is a silent killer—may not cause any symptoms initially but results in a target organ damage later.

Additionally, the administration of prophylactic calcium and or aspirin may have caused treatment paradox [84] that modified the effect of the risk factors on the development and outcomes of PE among the participants. The possible alteration of the circulating levels of angiogenic factors by aspirin reported in a previous study [85] is noted. However, only two normotensive and two sPE patients were on aspirin. The sFlt-1/PIGF ratios of these four participants were not consistently lower or higher than the median value of their respective groups (normotensive or sPE as applicable). Understandably, it may be argued that the aspirin therapy could have altered the levels of the sFlt-1/PIGF ratios. Most importantly, a recent study where aspirin was efficacious in preventing adverse pregnancy outcomes found the levels of angiogenic factors to be similar in users and non-users of aspirin [86]. The interpretation of this finding according to the investigators was that aspirin could be efficacious through other pathways other than altering the levels of angiogenic factors [86]. Another recent study did not find an association between every form of adherence to aspirin therapy and abnormal angiogenic markers [87]. Therefore, future studies are required to further investigate the effect of aspirin on circulating levels of angiogenic factors in different racial/population groups. Whether or not prenatal calcium supplementation alters the levels of angiogenic factors in pregnancy is largely unknown and requires further investigation in future studies. Nonetheless, the authors of the present study also note that there is a paucity of studies that indicate
whether and to what extent antihypertensive medications affect the circulating level of angiogenic factors in PE. Notably, antihypertensive medications do not alter the placental biosynthesis and or secretion of angiogenic factors in PE [88], but undoubtedly reduce BP levels.

Notably, due to poor distribution of numbers within groups, we were unable to calculate the predictive cut-off thresholds of sFlt-1/PIGF ratio and their diagnostic accuracies in subgroups of the participants. To explain, there was no participant in the normotensive group that received ≥ 3 slow- and/or rapid-acting antihypertensive agents, and as a result, the predictive ability of sFlt-1/PIGF ratio in the normotensive group alone could not be assessed. Therefore, future investigators of this topic should increase the sample size utilizing the findings of the present study in the power calculation to ensure that sufficient number of participants with EOPE and those with LOPE are sampled to optimize both the sensitivity and specificity. Unfortunately, the time duration of such a study and the cost implications may be an impediment, particularly in resource-constrained countries like South Africa. Additionally, the generalizability of the present study (even to patients having vaginal deliveries) is still limited until follow-up validation studies are conducted. To this end, plans are underway to commence the validation study.

The strength of this study includes the establishment of a much-needed optimal threshold of sFlt-1/PIGF ratio for predicting antihypertensive drug usage in the immediate postpartum period. Notably, hypertension is only second to Human Immunodeficiency Virus related illnesses as a cause of mortality in adults in Africa [89]. Therefore, the study addresses a research priority in the African continent being an observational study focused on events in the postpartum period after operative delivery [90]. To the best of our knowledge, the present study is the first of its kind to provide the cut-off thresholds of pre-delivery sFlt-1/PIGF ratio that may be utilized to predict the use of antihypertensive medications in the postpartum period in normotensive pregnancy and sPE.

Conclusion

The clinical management of sPE may be improved by utilizing sFlt-1/PIGF ratio to predict the antihypertensive requirements in the immediate postpartum period. Future large-scale studies are required to validate this finding.

Supporting information

S1 Table. The 2015 STARD (Standards for Reporting of Diagnostic Accuracy) 30-item checklist.

S2 Table. Statistically significant difference in the pre-delivery serum concentration of angiogenic factors between normotensive pregnancy and preeclampsia with severe features.

Acknowledgments

We are thankful to Roche for providing the sFlt-1 and PIGF reagents, the National Health Laboratory Service (in Edendale Hospital) for preservation of the blood samples, and to Ampath Laboratories in Westridge, Durban, South Africa for measuring the sFlt-1 and PIGF concentrations.
Author Contributions

Conceptualization: Nnabuike Chibuoke Ngene, Jagidesa Moodley.
Data curation: Nnabuike Chibuoke Ngene.
Formal analysis: Nnabuike Chibuoke Ngene.
Funding acquisition: Nnabuike Chibuoke Ngene.
Investigation: Nnabuike Chibuoke Ngene.
Methodology: Nnabuike Chibuoke Ngene, Jagidesa Moodley.
Project administration: Nnabuike Chibuoke Ngene, Jagidesa Moodley.
Resources: Nnabuike Chibuoke Ngene, Jagidesa Moodley, Thajasvarie Naicker.
Software: Nnabuike Chibuoke Ngene.
Supervision: Jagidesa Moodley.
Visualization: Nnabuike Chibuoke Ngene.
Writing – original draft: Nnabuike Chibuoke Ngene.
Writing – review & editing: Nnabuike Chibuoke Ngene, Jagidesa Moodley, Thajasvarie Naicker.

References

1. Pijnenborg R, Dixon G, Robertson WB, Brosens I. Trophoblastic invasion of human decidua from 8 to 18 weeks of pregnancy. Placenta 1980; 1(1):3–19. https://doi.org/10.1016/s0143-4004(80)80012-9. PMID: 7443635
2. Roberts JM, Hubel CA. The two stage model of preeclampsia: variations on the theme. Placenta 2009; 30 Suppl A:S32–7. https://doi.org/10.1016/j.placenta.2008.11.009 PMID: 19070896
3. Maynard SE, Min J-Y, Merchán J, Lim K-H, Li J, Mondal S, et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in pre-eclampsia. J Clin Invest 2003; 111(5):649–58. https://doi.org/10.1172/JCI17189 PMID: 12618519
4. Roberts JM, Redman CWG, Global Pregnancy Collaboration. Global Pregnancy Collaboration symposium: Prepregnancy and very early pregnancy antecedents of adverse pregnancy outcomes: Overview and recommendations. Placenta 2017;pii: S0143-4004(17):30661–6. https://doi.org/10.1016/j.placenta.2017.07.012.
5. Liu Z, Afink GB, Dijke PT. Soluble fms-like tyrosine kinase 1 and soluble endoglin are elevated circulating anti-angiogenic factors in pre-eclampsia. Pregnancy Hypertens 2012; 2(4):358–67. https://doi.org/10.1016/j.preghy.2012.06.003 PMID: 26105603
6. Roberts JM, Taylor RN, Musci TJ, Rodgers GM, Hubel CA, McLaughlin MK. Preeclampsia: an endothelial cell disorder. Am J Obstet Gynecol 1989; 161(5):1200–4. https://doi.org/10.1016/s0020-7292(89)90402-7. PMID: 2589440
7. Rodgers GM, Taylor RN, Roberts JM. Preeclampsia is associated with a serum factor cytotoxic to human endothelial cells. Am J Obstet Gynecol 1988; 159(5):908–14. https://doi.org/10.1016/s0002-9378(88)80169-8. PMID: 3177546
8. Agrawal S, Cerdeira AS, Redman C, Vatish M. Meta-Analysis and Systematic Review to Assess the Role of Soluble FMS-Like Tyrosine Kinase-1 and Placenta Growth Factor Ratio in Prediction of Pre-eclampsia: The SaPPPhirE Study. Hypertension 2017; 71(2):306. https://doi.org/10.1161/HYPERTENSIONAHA.117.110162 PMID: 29229743
9. Kenny LC, Black MA, Poston L, Taylor R, Myers JE, Baker PN, et al. Early pregnancy prediction of preeclampsia in nulliparous women, combining clinical risk and biomarkers: the Screening for Pregnancy Endpoints (SCOPE) international cohort study. Hypertension 2014; 64(3):644–52. https://doi.org/10.1161/HYPERTENSIONAHA.114.03578 PMID: 25122928
10. O’Brien M, Baczyk D, Kingdom JC. Endothelial Dysfunction in Severe Preeclampsia is Mediated bySoluble Factors, Rather than Extracellular Vesicles. Sci Rep 2017; 7(1):5887. https://doi.org/10.1038/s41598-017-06178-z PMID: 28725005
11. Leños-Miranda A, Méndez-Aguilar F, Ramírez-Valenzuela KL, Serrano-Rodríguez M, Berumen-Lechuga G, Molina-Pérez CJ, et al. Circulating angiogenic factors are related to the severity of gestational hypertension and preeclampsia, and their adverse outcomes. Medicine (Baltimore) 2017; 96(4):e6005. https://doi.org/10.1097/MD.0000000000006005.

12. Powers RW, Roberts JM, Cooper KM, Gallaher MJ, Frank MP, Harger GF, et al. Maternal serum soluble fms-like tyrosine kinase 1 concentrations are not increased in early pregnancy and decrease more slowly postpartum in women who develop preeclampsia. Am J Obstet Gynecol 2005; 193(1):185–91. https://doi.org/10.1016/j.ajog.2004.11.038 PMID: 16021077.

13. Douglas K, Redman C. Eclampsia in the United Kingdom. BMJ 1994; 309(6966):1395–400. https://doi.org/10.1136/bmj.309.6966.1395. PMID: 7819945.

14. Moodley J, Kalane G. A review of the management of eclampsia: practical issues. Hypertens Pregnancy 2006; 25(2):47–62. https://doi.org/10.1080/10641950500543897 PMID: 16867912.

15. Nathan HL, Seed P, Hezelflage NL, De Greeff A, Lawley E, Conti-Ramsden F, et al. Maternal and perinatal adverse outcomes in women with pre-eclampsia cared for at facility-level in South Africa: a prospective cohort study. J Glob Health 2018; 8(2):e020401. https://doi.org/10.7189/jogh.08-020401 PMID: 30140431.

16. Makris A, Yeung KR, Lim SM, Sunderland N, Heffernan S, Thompson JF, et al. Placental Growth Factor Reduces Blood Pressure in a Uteroplacental Ischemia Model of Preeclampsia in Nonhuman Primates. Hypertension 2016; 67(1263–1272):1263. https://doi.org/10.1161/HYPERTENSIONAHA.116.07286.

17. Ngene NC, Moodley J. Physiology of blood pressure relevant to managing hypertension in pregnancy. J Matern Fetal Neonatal Med 2019; 32(8):1368–477. https://doi.org/10.1080/14767058.2017.1404569.

18. Troisi R, Braecke K, Harsem NK, Hyer M, Hoover RN, Staff AC. Blood pressure augmentation and maternal circulating concentrations of angiogenic factors at delivery in preeclamptic and uncomplicated pregnancies. Am J Obstet Gynecol 2008; 199(6):e1–10. https://doi.org/10.1016/j.ajog.2008.06.030.

19. Goel A, Maski MR, Bajracharya S, Wenger JB, Zhang D, Salahuddin S, et al. Epidemiology and Mechanisms of De Novo and Persistent Hypertension in the Postpartum Period. Circulation 2015; 132(18):1726–33. https://doi.org/10.1161/CIRCULATIONAHA.115.015721 PMID: 26416810.

20. Yang J, Pearl M, DeLorenze GN, Rome R, Dong Z, Jelliffe-Pawlowski L, et al. Racial-ethnic differences in midtrimester maternal serum levels of angiogenic and antiangiogenic factors. Am J Obstet Gynecol 2016; 215(3):359.e1–9. https://doi.org/10.1016/j.ajog.2016.04.002.

21. Ngene NC, Moodley J. Role of angiogenic factors in the pathogenesis and management of pre-eclampsia. Int J Gynaecol Obstet 2018; 141(1):5–13. https://doi.org/10.1002/ijgo.12424.

22. Nathan HL, Seed P, Hezelgrave NL, De Greeff A, Lawley E, Conti-Ramsden F, et al. Maternal and perinatal adverse outcomes in women with pre-eclampsia cared for at facility-level in South Africa: a prospective cohort study. J Glob Health 2018; 8(2):020401. https://doi.org/10.7189/jogh.08-020401 PMID: 30140431.

23. Moodley J, Ngene NC. Spontaneous liver haematoma rupture associated with pre-eclampsia in a low-to-middle-income country: Lessons to be learnt from maternal death assessments. S Afr Med J 2018; 108(10):809–12. https://doi.org/10.7196/SAMJ.2018.v108i10.13280.

24. Abalos E, Cuesta C, Grosso AL, Chou D, Say L. Global and regional estimates of preeclampsia and eclampsia: a systematic review. Eur J Obstet Gynecol Reprod Biol 2013; 170(1):1–7. https://doi.org/10.1016/j.ejogrb.2013.05.005 PMID: 23746796.

25. Moodley J, Onyangunha O, Maharaj N. Hypertensive disorders in primigravid black South African women: A one-year descriptive analysis. Hypertens Pregnancy 2016; 35(4):529–35. https://doi.org/10.1080/10641955.2016.1193190 PMID: 27391770.

26. Allen SE, Titia A, Anderson S, Biggio JR, Harper DL. Is use of multiple antihypertensive agents to achieve blood pressure control associated with adverse pregnancy outcomes? J Perinatol 2017; 37(4):340–4. https://doi.org/10.1038/pj.2016.247 PMID: 28079872.

27. Ngene N, Moodley J, von Rahden R, Paruk F, Machinga P. Avoidable factors associated with pregnant and postpartum patients admitted to two intensive care units in South Africa. S Afr J Obstet Gynaecol 2016; 22(1):8–12. https://doi.org/10.7196/SAJOG.2016.v22i1.1033.

28. Verloren S, Galindo A, Schlembach D, Zeisler H, Herraiz I, Moertl MG, et al. An automated method for determination of the sFlt-1/PIGF ratio in the assessment of preeclampsia. Am J Obstet Gynecol 2010; 202(2):161.e1–e11. https://doi.org/10.1016/j.ajog.2009.09.016.

29. Wright D, Krajeswiska K, Bogdanova A, Wright A, Nicolaides KH. Maternal serum soluble fms-like tyrosine kinase-1 at 22 and 32 weeks in the prediction of preeclampsia. Ultrasound Obstet Gynecol 2016; 47(6):755–61. https://doi.org/10.1002/uog.15850 PMID: 26726123.
30. Ukah UV, Hutcheon JA, Payne B, Haslam MD, Vatishe M, Ansermin JM, et al. Placental Growth Factor as a Prognostic Tool in Women With Hypertensive Disorders of Pregnancy: A Systematic Review. Hypertension 2017; 70(6):1228–37. https://doi.org/10.1161/HYPERTENSIONAHA.117.10150 PMID: 29084878

31. Brown M, Magee LA, Kenny LC, Karumanchi SA, McCarthy F, Saito S, et al. The hypertensive disorders of pregnancy: ISSHP classification, diagnosis & management recommendations for international practice. Pregnancy Hypertens 2018; 13:291–310. https://doi.org/10.1016/j.preghy.2018.05.004 PMID: 29803330

32. National Collaborating Centre for Women’s and Children’s Health. Hypertension in pregnancy: the management of hypertensive disorders during pregnancy 2011. Available from: https://www.nice.org.uk/guidance/cg107/evidence/cg107-hypertension-in-pregnancy-full-guideline3 (accessed 7 January 2019).

33. Lowe S, Bowyer L, Lust K, McMahon L, Morton M, North R, et al. SOMANZ guidelines for the management of hypertensive disorders of pregnancy 2014. Aust N Z J Obstet Gynaecol 2015; 55(5):e1–29. https://doi.org/10.1111/ajo.12399 PMID: 26412014

34. National Institute for Health and Clinical Excellence. Hypertension in pregnancy: the management of hypertensive disorders during pregnancy. NICE clinical guideline 107 2010. Available from: https://www.nice.org.uk/guidance/cg107/resources/hypertension-in-pregnancy-diagnosis-and-management-35109334009285 (accessed 31 December 2016).

35. ACOG. Practice Bulletin No. 202: Gestational Hypertension and Preeclampsia. Obstet Gynecol 2019; 133(1):e1–e25. https://doi.org/10.1097/AOG.00000000000033018 PMID: 30575675

36. Society of Obstetricians and Gynaecologists of Canada (SOGC). Clinical Practice Guidelines. Diagnosis, Evaluation, and Management of the Hypertensive Disorders of Pregnancy: Executive Summary. No. 307. J Obstet Gynaecol Can 2014; 36(5):416–38. PMID: 24927294

37. Tranquilli AL, Brown MA, Zeeman GG, Dekker G, Sibai BM. The definition of severe and early-onset preeclampsia. Statements from the International Society for the Study of Hypertension in Pregnancy (ISSHP). Pregnancy Hypertens 2013; 3(1):44–7. https://doi.org/10.1016/j.preghy.2012.11.001 PMID: 26105740

38. Regitz-Zagrosek V, Roos-Hesselink JW, Bauserschs J, Blomström-Lundqvist C, Ci-testová R, De Bonis M, et al. 2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy. Eur Heart J 2018; 39(34):3165–241. https://doi.org/10.1093/eurheartj/ehy340 PMID: 30185544

39. Ngene NC, Moodley J. Baseline check of blood pressure readings of an automated device in severe pre-eclampsia and healthy normotensive pregnancy. Pregnancy Hypertens 2018; 12:47–52. https://doi.org/10.1016/j.preghy.2018.02.013 PMID: 29674198

40. Hypertension guideline working group: Seedat YK, Rayner B, Veriava Y. South African Hypertension Guideline 2014. Cardiovasc J Afr 2014; 25(6):288–94. https://doi.org/10.5830/CVJA-2014-062 PMID: 25629715

41. Roche Diagnostics GmbH. Elecsys sFlt-1 Immunoassay, Package Insert (ms_05109523190.V9.en). Sandhofer Strasse 116, D-68305 Mannheim, Germany 2018.

42. Roche Diagnostics GmbH. Elecsys PlGF Immunoassay, Package Insert (ms_05144671190.V10.en). Sandhofer Strasse 116, D-68305 Mannheim, Germany 2018.

43. National Department of Health Republic of South Africa. Guidelines for maternity care in South Africa: A manual for clinics, community health centres and district hospitals 2015. Available from: https://www.health-e.org.za/wp-content/uploads/2015/11/Maternal-Care-Guidelines-2015_FINAL-21.7.15.pdf (accessed 14 July 2018).

44. Lambert G, Brichant JF, Hartstein G, Bonhomme V, Dewandre PY. Preeclampsia: an update. Acta Anaesthesiol Belg 2014; 65(4):137–49. PMID: 25622379.

45. American College of Obstetricians and Gynecologists (ACOG) Committee on Obstetric Practice, Committee Opinion No. 692: Emergent Therapy for Acute-Onset, Severe Hypertension During Pregnancy and the Postpartum Period. Obstet Gynaecol 2017; 129(4):e90–e5. https://doi.org/10.1097/AOG.0000000000002019.

46. Moodley J, Ngene NC. Severe hypertension in pregnancy: using dynamic checklist to save lives. S Afr Med J 2016; 106(8):767–70. https://doi.org/10.7196/SAMJ.2016.v106i.10098 PMID: 27499397

47. Liu H, Wu T. Estimating the Area under a Receiver Operating Characteristic Curve For Repeated Measures Design. J Stat Softw 2003; 8(12):1–18. https://doi.org/10.18637/jss.v008.i12.

48. Ghasemi A, Zahediasl S. Normality Tests for Statistical Analysis: A Guide for Non-Statisticians. Int J Endocrinol Metab 2012; 10(2):486–9. https://doi.org/10.5812/ijem.3505 PMID: 23843808

49. Barton B, Peat J. Medical statistics: A guide to SPSS, data analysis and critical appraisal. 2nd ed. West Sussex, UK: John Wiley & Sons Ltd; 2014.
66. Zeisler H, Llurba E, Chantrain e F, Vatish M, Staff A, Sennstr o¨ m M, et al. Predictiv e Value of the sFlt-1:
67. Gomath y E, Akurati L, Radhika K. Early onset and late onset preeclam psia-mate rnal and perinatal out-
65. Matjila M, Anthony J, Vatish M, Moodley J, Bhorat I, Nicolaou E, et al. Consens us statement on the
69. Ngene NC, Moodley J. Postpar tum blood pressure patterns in severe preeclamp sia and normoten sive
64. National Institute for Health and Care Excellence . PlGF-based testing to help diagno se suspected pre-
63. Cohen JF, Koreva ar DA, Altman DG, Bruns DE, Gatsonis CA, Hooft L, et al. STARD 2015 guidelines
57. Kaitu'u-Lin o TJ, Brownfoot FC, Beard S, Cannon P, Hastie R, Nguyen TV, et al. Combining metformin
55. Youden WJ. Index for rating diagnostic tests. Cancer 1950; 3(1):32–5. https://doi.or g/10.1002/1097-
56. Mandrekar JN. Receiver operating character istic curve in diagnos tic test assessmen t. J Thorac Oncol 2010;
52. Russell J. The Statistics tutor’s quick guide to commonly used statistical tests. Available from: http://
50. Pallant J. SPSS survival manual: A step by step guide to data analysis using SPSS. 4 ed. Crows Nest, Australia: Allen and Unwin; 2011.
51. Russell J. Statistical and data data analysis in medicine: principles and practice. Melbourne, Australia: Elsevier; 2006.
53. Mandrekar JN. Simple statistical measures for diagnostic accuracy assessment. J Thorac Oncol 2010; 5(6):763–4. 
54. Momeni A, Pincus M, Libien J. Introduction to statistical methods in pathology. Cham, Switzerland: Springer International Publishing AG; 2018.
58. EQUATOR (Enhancing the QUAlity and Transparency Of health Research) Network. STARD 2015: An
59. Govender L, Mackraj I, Gathiram P, Moodley J. The role of angiogenic, anti-angiog enic and vasoactiv e
60. Cerdeira AS, Agrawal S, Staff AC, Redman CW, Vatish M. Angiogenic factors: potentia l to change clini-
61. Youden WJ. Index for rating diagnostic tests. Cancer 1950; 3(1):32–5. https://doi.or g/10.1002/1097-
62. Cohen JF, Korevaar DA, Altman DG, Bruns DE, Gatsonis CA, Hooft L, et al. STARD 2015 guidelines
63. Cohen JF, Korevaar DA, Altman DG, Bruns DE, Gatsonis CA, Hooft L, et al. STARD 2015 guidelines
64. National Institute for Health and Care Excellence . PlGF-based testing to help diagno se suspected pre-
65. Mandrekar JN. Receiver operating character istic curve in diagnos tic test assessmen t. J Thorac Oncol 2010;
66. Zeisler H, Llurba E, Chantrain e F, Vatish M, Staff A, Sennstr o¨ m M, et al. Predictiv e Value of the sFlt-1:
67. Gomath y E, Akurati L, Radhika K. Early onset and late onset preeclam psia-mate rnal and perinatal out-
68. Li XL, Guo PL, Xue Y, Gou W, Tong M, Chen Q. An analysis of the differences between early and late preeclampsia with severe hypertension. Pregnancy Hypertens 2016; 6(1):47–52. https://doi.org/10.1016/j.preghy.2015.12.003 PMID: 26955772
69. Ngene NC, Moodley J. Postpartum blood pressure patterns in severe preeclampsia and normoten sive

70. Staff AC, Redman CWG. The Differences Between Early- and Late-Onset Pre-eclampsia. In: Saito S, editor. Preeclampsia: Basic, Genomic, and Clinical. Comprehensive Gynecology and Obstetrics. Singapore: Springer Nature; 2018. p. 157–72.

71. Varnier N, Brown MA, Reynolds M, Petit F, Davis G, Mangos G, et al. Indications for delivery in pre-eclampsia. Pregnancy Hypertens 2018; 11:12–7. https://doi.org/10.1016/j.preghy.2017.11.004 PMID: 29523266

72. Stolz M, Zeisler H, Heinzl F, Binder J, Farr A. An sFlt-1/PIGF ratio of 655 is not a reliable cut-off value for predicting perinatal outcomes in women with preeclampsia. Pregnancy Hypertens 2018; 11:54–60. https://doi.org/10.1016/j.preghy.2018.01.001 PMID: 29523274

73. Ukah UV, Mbofana F, Rocha BM, Loquilia O, Mudenyanga C, Usta M, et al. Diagnostic Performance of Placental Growth Factor in Women With Suspected Preeclampsia Attending Antenatal Facilities in Maputo, Mozambique. Hypertension 2017; 69(3):469–74. https://doi.org/10.1161/HYPERTENSIONAHA.116.08547 PMID: 28137987

74. Roberts JM, Bell MJ. If we know so much about preeclampsia, why haven’t we cured the disease? J Reprod Immunol 2013; 99(1–2):1–9. https://doi.org/10.1016/j.jri.2013.05.003 PMID: 23890710

75. Paulino-Morente JMA, Cacas-David IG, Penolit VVL. Association of hypokalemia and preeclampsia and correlation of levels of serum potassium to blood pressure severity in preeclampsia. Philipp J Obstet Gynecol 2018; 42(2):9–16.

76. Rana S, Schnettler WT, Powe C, Wenger J, Salahuddin S, Cerdeira AS, et al. Clinical characterization and outcomes of preeclampsia with normal angiogenic profile. Hypertens Pregnancy 2013; 32(2):189–201. https://doi.org/10.3109/10641955.2013.784788 PMID: 23725084

77. Verlohren S, Perschel FH, Thilaganathan B, Droege LA, Henrich W, Busjahn A, et al. Angiogenic Markers and Cardiovascular Indices in the Prediction of Hypertensive Disorders of Pregnancy. Hypertension 2017; 69(6):1192–7. https://doi.org/10.1161/HYPERTENSIONAHA.117.09256 PMID: 28461601

78. Ngene NC, Moodley J. Blood pressure measurement and rapid acting antihypertensives for severe hypertension in pregnancy. Obstetrics and Gynaecology Forum. 2016; 26(3):35–40.

79. Sibai BM. Etiology and management of postpartum hypertension-preeclampsia. Am J Obstet Gynecol 2012; 206(6):470–5. https://doi.org/10.1016/j.ajog.2011.09.002 PMID: 21963308

80. Hall D. Treatment of hypertension during pregnancy. SA Heart 2014; 11(2):68–74. https://doi.org/10.24170/11-2-1758.

81. Ngene N, Onyia C, Moodley J, Titus M. Needlestick injury in a pregnant inpatient in an overcrowded hospital. South Afr J HIV Med 2014; 15(2):66–8. https://doi.org/10.7196/sajhivmed.1048.

82. Badenhorst DHS, van der Westhuizen CA, Britz E, Burger MC, Ferreira N. Lost to follow-up : Challenges to conducting orthopaedic research in South Africa. S Afr Med J 2018; 108(11):917–21. https://doi.org/10.7196/SAMJ.2018.v108i11.13252 PMID: 30645956

83. Limaye M, Srivivas SK, Levine LD. Clinical Factors Associated With Lower Postpartum Follow-up Among Women With Severe Preeclampsia [75]. Obstet Gynaecol 2015; 125(5):(Suppl 1)31S. https://doi.org/10.1097/AOG.0000462768.95808.02.

84. Magee LA, von Dadelszen P, Singer J, Lee T, Rey E, Ross S, et al. Can adverse maternal and perinatal outcomes be predicted when blood pressure becomes elevated? Secondary analyses from the CHIPS (Control of Hypertension In Pregnancy Study) randomized controlled trial. Acta Obstet Gynecol Scand 2016; 95(7):763–76. https://doi.org/10.1111/aogs.12877 PMID: 26915709

85. Murtoniem K, Vahlberg T, Hämäläinen E, Kajantie E, Pesonen AK, Rääkkönen K, et al. The effect of low-dose aspirin on serum placental growth factor levels in a high-risk PREDO cohort. Pregnancy Hypertens 2018; 13:51–7. https://doi.org/10.1016/j.preghy.2018.04.003 PMID: 30177071

86. Kim MY, Buyon JP, Guerra MM, Rana S, Zhang D, Laskin CA, et al. Angiogenic factor imbalance early in pregnancy predicts adverse outcomes in patients with lupus and antiphospholipid antibodies: results of the PROMISSE study. Am J Obstet Gynecol 2016; 214(1):108.e1–e14. https://doi.org/10.1016/j.ajog.2015.09.066.

87. Navaratnam K, Abreu P, Clarke H, Jorgensen A, Alfivreic A, Alfivreic Z. Evaluation of agreement of placental growth factor (PIGF) tests and the soluble FMS-like tyrosine kinase 1 (sFlt-1)/PIGF ratio, comparison of predictive accuracy for pre-eclampsia, and relation to uterine artery Doppler and response to aspirin. J Matern Fetal Neonatal Med 2019; 32(2):179–87. https://doi.org/10.1080/14767058.2017.1373760 PMID: 28851242

88. Gangoozy S, Muttukrishna S, Jauniaux E. In-vitro study of the effect of anti-hypertensive drugs on placental hormones and angiogenic proteins synthesis in pre-eclampsia. PLoS ONE. 2014; 9(9):e107644. https://doi.org/10.1371/journal.pone.0107644 PMID: 25251016
89. Dzudie A, Rayner B, Ojji D, Schutte AE, Twagirumukiza M, Damasceno A, et al. Roadmap to Achieve 25% Hypertension Control in Africa by 2025. Glob Heart 2018; 13(1):45–59. https://doi.org/10.1016/j.gheart.2017.06.001 PMID: 29042191

90. Ntusi N. Perioperative evaluation of patients who are due to undergo surgery. S Afr Med J 2018; 108 (5):367–8. https://doi.org/10.7196/SAMJ.2018.v108i5.13329.